1 research outputs found
Discovery and Rational Design of Pteridin-7(8<i>H</i>)‑one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants
FLT3 has been validated as a therapeutic
target for the treatment of acute myeloid leukemia (AML). In this
paper, we describe for the first time, pteridin-7Â(8<i>H</i>)-one as a scaffold for potent FLT3 inhibitors derived from structural
optimizations on irreversible EGFR inhibitors. The representative
inhibitor (<b>31</b>) demonstrates single-digit nanomolar inhibition
against FLT3 and subnanomolar <i>K</i><sub>D</sub> for drug-resistance
FLT3 mutants. In profiling of the in vitro tumor cell lines, it shows
good selectivity against AML cells harboring FLT3-ITD mutations over
other leukemia and solid tumor cell lines. The mechanism of action
study illustrates that pteridin-7Â(8<i>H</i>)-one derivatives
suppress the phosphorylation of FLT3 and its downstream pathways,
thereby inducing G<sub>0</sub>/G<sub>1</sub> cell cycle arrest and
apoptosis in AML cells. In in vivo studies, <b>31</b> significantly
suppresses the tumor growth in MV4–11 xenograft model. Overall,
we provide a structurally distinct chemical scaffold with which to
develop FLT3 mutants-selective inhibitors for AML treatment